Now live: Watch episodes 3 and 4 of our new Peer Exchange series, "Emerging Treatment Options for Recurrent C. Difficile Infection." #CDiff https://t.co/BywcFbQHAD
Now live: Watch episodes 3 and 4 of our new Peer Exchange series, "Emerging Treatment Options for Recurrent C. Difficile Infection." #CDiffhttps://t.co/BywcFbQHAD pic.twitter.com/ZOb9ZiqJkc— Contagion (@Contagion_Live) August 24, 2022
Nurses' knowledge, practices and perceptions regarding Clostridioides difficile: Survey results
Respondents identified many factors that could contribute to less-than optimal care and management of inpatients with CDI, and identified some solutions that would facilitate the provision of best practice. An educational intervention, with emphasis on the areas of greatest knowledge deficits, has b …
Ferring Microbiome on Twitter
Need help talking about your C. diff symptoms? This checklist https://t.co/QGohasBjUt can help you get past any embarrassment. With this useful tool you can note your individual symptoms for an easier conversation with your doctor. #FerringMicrobiome #Cdiff pic.twitter.com/LdnQb6QuC9— Ferring Microbiome (@FerringMBiome) August 23, 2022
Development of a clinical prediction model for recurrence and mortality outcomes after Clostridioides difficile infection using a machine learning approach
XGBoost performed slightly better than logistic regression for predicting recurrence, but it was not competitive with existing published models. Despite this, a future machine learning-based application provided in a bedside setting at low cost might be a clinically useful tool.
Impact of Statewide Prevention and Reduction of Clostridioides difficile (SPARC), a Maryland public health-academic collaborative: an evaluation of a quality improvement intervention - PubMed
To evaluate changes in Clostridioides difficile incidence rates for Maryland hospitals that participated in the Statewide Prevention and Reduction of C. difficile (SPARC) collaborative. Pre-post, difference-in-difference analysis of non-randomised intervention using four quarters of pr …
Efficacy of Omadacycline or Vancomycin Combined with Germinants for Preventing Clostridioides difficile Relapse in a Murine Model - PubMed
In murine models of CDI, omadacycline improved survival versus vancomycin. Germinant-antibiotic combinations were more effective at preventing rCDI compared to antibiotics alone without inducing toxin production.
Application of consolidated framework for implementation research to improve Clostridioides difficile infection management in district hospitals
This research provides a straight-forward health systems strengthening intervention for CDI that is both needed and uncomplicated, in an understudied low resource setting. Intervention uptake was highest in the hospital with tension for change, influential champions, and existing academic partnershi …
Welcome! You are invited to join a webinar: ESNM-GMFH Webinar 05 "Treatment options for CDI". After registering, you will receive a confirmation email about joining the webinar.
Treatment options for CDI Chair: Giovanni Barbara, Bologna, Italy First-line management, Nicola Petrosillo, Rome, Italy Faecal Microbiota Transplantation (FMT), Gianluca Ianiro (TBC) Followed by Q&A with chairs and speakers
A Prediction Model Incorporating Peripheral Eosinopenia as a Novel Risk Factor for Death After Hospitalization for Clostridioides difficile Infection
Among adults hospitalized with CDI, peripheral eosinopenia was associated with increased risk of all-cause 30-day mortality. A prediction model incorporating peripheral eosinopenia was developed to improve care for hospitalized patients with CDI through risk stratification.
RT @john_damianosMD: Vancomycin 🆚 fidaxomicin for Clostridioides difficile infection 💊FDX ⬆️ global cure rates 💊FDX ⬇️ recurrence rate 💊co…
Vancomycin 🆚 fidaxomicin for Clostridioides difficile infection💊FDX ⬆️ global cure rates💊FDX ⬇️ recurrence rate💊comparable clinical cure rates💊comparable adverse events🥇FDX is superior to VCM in CDI❗️#MedTwitter #GITwitter #IDTwitter #Cdiffhttps://t.co/LRqeiviHg5— John Damianos, M.D. (@john_damianosMD) August 16, 2022
Oral fidaxomicin versus vancomycin for the treatment of Clostridioides difficile infection: A systematic review and meta-analysis of randomized controlled trials
Fidaxomicin (FDX) has received considerable attention as a novel therapeutic alternative agent to vancomycin (VCM) for Clostridioides difficile infect…
Oral fidaxomicin versus vancomycin for the treatment of Clostridioides difficile infection: A systematic review and meta-analysis of randomized controlled trials
FDX achieves significantly higher global cure rates and lower recurrence rates and is comparable to VCM in clinical cure rates and adverse event rates in patients with CDI. Collectively, FDX is superior to VCM as a therapeutic agent for CDI.
The Efficacy of Bezlotoxumab in the Prevention of Recurrent Clostridium difficile: A Systematic Review - Cureus
Clostridium difficile infection (CDI) is the most common nosocomial infection in hospitals. Despite the fact that CDI has treatment options, recurrence is common after the treatment, recurrence ...
Cefiderocol use in Gram negative infections with limited therapeutic options: Is combination therapy the key?
To date, no differences have been demonstrated between cefiderocol monotherapy or combination. Further studies are required to understand whether cefiderocol combination therapy could provide an advantage in outcome in seriously-ill patients.
APIC on Twitter
WEBINAR: APIC & SIS Webinar: ID vs Surgeon Symposium | 8/17 | 4 PM ET. Presenters will disuss #Cdiff infection, necrotizing soft tissue infections, diabetic foot infections, and infected vascular catheters, etc. Register now: https://t.co/Hkm0tcFAFm pic.twitter.com/8nDwnmhWwz— APIC (@APIC) August 8, 2022
Sahil Khanna, MBBS, MS, FACG, AGAF on Twitter
#Bezlotoxumab in addition to an antibiotic prevents recurrent #Cdiff up to 12 weeks!Useful if one or more of these present:➡️Age 65➡️C.diff in the last 6 months➡️Immunocompromised➡️Severe #CdiffDo not use in heart failure patients pic.twitter.com/kAeiHHFIHn— Sahil Khanna, MBBS, MS, FACG, AGAF (@Khanna_S) July 30, 2022
RT @ibdlearn: ⚡️QUICK SHOT⚡️ What’s your next step in treating recurrent #CDiff in a patient with UC on Stelara failed by vanco taper? 💉h…
⚡️QUICK SHOT⚡️What’s your next step in treating recurrent #CDiff in a patient with UC on Stelara failed by vanco taper?💉https://t.co/YoexFSGC4K💉@UmaMahadevanIBD @GIMedEd @colin_feuille #IBD #GITwitter #Meded #FOAMEd @MondayNightIBD @ucsfibd @UCSFGIfellows— IBDLearn (@ibdlearn) August 4, 2022
Study of the gut microbiome in Egyptian patients with active ulcerative colitis
The current study showed differences in the gut microbiome of UC patients, compared with healthy controls. This may help in identifying the gut microbiome and specific bacterial changes that can be targeted for treatment of UC.